BioMarin Pharmaceutical segnala gli utili su base trimestrale. Questi report sugli utili trimestrali offrono agli investitori uno sguardo ai risultati finanziari di un'azienda per un periodo di 3 mesi. I report sugli utili includono quasi sempre i risultati EPS e i ricavi.
Analizza lo storico degli utili di BioMarin Pharmaceutical utilizzando ordinamenti e filtri avanzati.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
BMRN | Biomarin Pharmaceutical | $0.91 | $0.51 | $0.12 | -76.47% | $745.74M | $781.89M | $776.13M | -0.74% | 10/27/2025 | |
BMRN | Biomarin Pharmaceutical | $0.96 | $0.93 | $1.44 | 54.84% | $712.03M | $763.49M | $825.41M | 8.11% | 08/04/2025 | |
BMRN | Biomarin Pharmaceutical | $0.71 | $0.71 | $1.13 | 59.15% | $648.83M | $740.72M | $745.14M | 0.60% | 05/01/2025 | |
BMRN | Biomarin Pharmaceutical | $0.49 | $0.74 | $0.92 | 24.32% | $646.21M | $711.05M | $747.00M | 5.06% | 02/19/2025 | |
BMRN | Biomarin Pharmaceutical | $0.46 | $0.52 | $0.91 | 75.00% | $581.33M | $700.14M | $745.74M | 6.51% | 10/29/2024 | |
BMRN | Biomarin Pharmaceutical | $0.54 | $0.35 | $0.96 | 174.29% | $595.27M | $661.23M | $712.03M | 7.68% | 08/05/2024 | |
BMRN | Biomarin Pharmaceutical | $0.60 | $0.34 | $0.71 | 108.82% | $596.41M | $651.79M | $648.83M | -0.45% | 04/24/2024 | |
BMRN | Biomarin Pharmaceutical | $0.00 | $0.23 | $0.49 | 113.04% | $537.54M | $636.67M | $646.21M | 1.50% | 02/22/2024 | |
BMRN | Biomarin Pharmaceutical | -$0.04 | $0.22 | $0.46 | 109.09% | $505.34M | $608.33M | $581.33M | -4.44% | 11/01/2023 | |
BMRN | Biomarin Pharmaceutical | $0.15 | $0.47 | $0.54 | 14.89% | $533.80M | $591.46M | $595.27M | 0.65% | 07/31/2023 | |
BMRN | Biomarin Pharmaceutical | $0.63 | $0.18 | $0.60 | 233.33% | $519.36M | $570.62M | $596.41M | 4.52% | 04/26/2023 | |
BMRN | Biomarin Pharmaceutical | -$0.32 | -$0.07 | $0.00 | 100.00% | $449.81M | $536.97M | $537.54M | 0.11% | 02/27/2023 | |
BMRN | Biomarin Pharmaceutical | -$0.20 | -$0.01 | -$0.04 | -300.00% | $408.74M | $518.91M | $505.34M | -2.61% | 10/26/2022 | |
BMRN | Biomarin Pharmaceutical | $0.07 | $0.11 | $0.59 | 436.36% | $501.69M | $521.47M | $533.80M | 2.36% | 08/03/2022 | |
BMRN | Biomarin Pharmaceutical | $0.09 | — | $0.17 | — | $486.03M | $507.52M | $519.36M | 2.33% | 04/27/2022 | |
BMRN | Biomarin Pharmaceutical | $0.12 | -$0.32 | -$0.32 | 0.00% | $452.12M | $442.39M | $449.81M | 1.68% | 02/23/2022 | |
BMRN | Biomarin Pharmaceutical | $4.01 | -$0.25 | -$0.20 | 20.00% | $476.78M | $435.32M | $408.74M | -6.11% | 10/27/2021 | |
BMRN | Biomarin Pharmaceutical | -$0.16 | -$0.11 | $0.07 | 163.64% | $429.49M | $448.79M | $501.69M | 11.79% | 07/28/2021 | |
BMRN | Biomarin Pharmaceutical | $0.44 | -$0.10 | $0.09 | 190.00% | $502.07M | $446.45M | $486.03M | 8.87% | 04/29/2021 | |
BMRN | Biomarin Pharmaceutical | $0.08 | -$0.19 | $0.12 | 163.16% | $454.44M | $440.23M | $452.12M | 2.70% | 02/25/2021 | |
BMRN | Biomarin Pharmaceutical | $0.30 | $1.29 | $4.01 | 210.85% | $461.10M | $454.64M | $476.78M | 4.87% | 11/05/2020 |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q3 | 2025-10-27 | $0.12 | $0.51 | -76.5 % |
| Q2 | 2025-08-04 | $1.44 | $0.93 | 54.8 % |
| Q1 | 2025-05-01 | $1.13 | $0.71 | 59.2 % |
| Q4 | 2025-02-19 | $0.92 | $0.74 | 24.3 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q3 | 2025-10-27 | $776.13M | $781.89M | -0.74 % |
| Q2 | 2025-08-04 | $825.41M | $763.49M | 8.11 % |
| Q1 | 2025-05-01 | $745.15M | $740.72M | 0.60 % |
| Q4 | 2025-02-19 | $747.00M | $711.05M | 5.06 % |
BioMarin Pharmaceutical (BMRN) non ha ancora previsto report sulle performance. L'ultimo report sui risultati è stato pubblicato il ottobre 27, 2025 per il Q3.
BioMarin Pharmaceutical (BMRN) non ha ancora in programma alcun report sugli utili. L'ultimo report sugli utili è stato pubblicato il ottobre 27, 2025 per il Q3 e l'EPS effettivo è stato $0.12, che mancato la stima di $0.51.
BioMarin Pharmaceutical (BMRN) non ha ancora pianificato alcun report sugli utili. L'ultimo report sugli utili è stato pubblicato il ottobre 27, 2025 per il Q3 e i ricavi effettivi sono stati $776.1M, che mancato la stima di $781.9M.
Sfoglia stime sugli utili, EPS e ricavi su tutte le azioni.